Actualités Satellos Bioscience Inc - MSCL | Actions Toronto Stock Exchange

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

- Marks successful completion of full enrollment of SAD cohorts and the first two MAD cohorts in the healthy volunteer study - Up to 10 adult...

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (“Satellos”), a public biotech company developing new small molecule therapeutic approaches to...

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule...

Satellos Appoints Stephanie Brown to Board of Directors

Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule...

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no...

Satellos to Participate in November 2024 Investor Conferences

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule...

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps...

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in...

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule...

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”...

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at...

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

– SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is...

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of...

Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)

–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine...

Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference

– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Satellos Bioscience Inc (MSCL)

Outils de qualité professionnelle, pour des investisseurs individuels.

MSCL Actualités

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Appoints Stephanie Brown to Board of Directors

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

Satellos to Participate in November 2024 Investor Conferences

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)

Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Satellos Bioscience Inc (MSCL) Actualités

Satellos Bioscience Inc (MSCL)

Outils de qualité professionnelle, pour des investisseurs individuels.

MSCL Actualités

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Appoints Stephanie Brown to Board of Directors

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

Satellos to Participate in November 2024 Investor Conferences

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)

Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application